University of Giessen Lung Center

Funding Ralph Schermuly

• Deutsche Forschungsgemeinschaft (DFG), SFB 547 „Cardiopulmonary Vasculature“: Project C6 „Phosphodiesterase Inhibitors and activators/stimulators of soluble guanylate cyclase for induction of reverse-remodeling in pulmonary hypertension”
• Deutsche Forschungsgemeinschaft (DFG), SFB 547 „Cardiopulmonary Vasculature“: Project B 11 „Tyrosine kinase inhibition as antiproliferative therapy of pulmonary diseases”
• Deutsche Forschungsgemeinschaft (DFG), KFO118 „Pathomechanismen und Therapie der Lungenfibrose“, TP3 : "Mechanisms and therapeutic strategies of alveolo- and vasculogenesis in lung development: Role of bronchopulmonary dysplasia (BPD)”
• Deutsche Forschungsgemeinschaft (DFG), International Graduate College (GRK 1062) „Signaling Mechanisms in Lung Physiology and Disease": Project leader "Animal Models of Pulmonary Hypertension”
• Bundesministerium für Bildung und Forschung (BMBF), Project leader „Local delivery of siRNA targeting the TGF-beta pathway in idiopathic pulmonary fibrosis”
• Else Kröner Fresenius Foundation: „Development of innovative inhalative therapies for treatment of pulmonary hypertension”
• Else Kröner Fresenius Foundation: „Endothelial dysfunction in pulmonary hypertension”
• Excellence Cluster "Cardiopulmonary System" (ECCPS): Platform leader „Techniques and Technology Development”
• 6th Framework Program European Union „Pulmotension”, Steering Committee member, Areas G and F